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Treatment intensification to maximize disease control and reducedintensity approaches to minimize the risk of late sequelae havebeen evaluated in newly diagnosed Hodgkin lymphoma. The
influence of these interventions on the risk of secondary malignant neo-
plasms, progression-free survival and overall survival is reported in the
meta-analysis herein, based on individual patient data from 9498
patients treated within 16 randomized controlled trials for newly diag-
nosed Hodgkin lymphoma between 1984 and 2007. Secondary malig-
nant neoplasms were meta-analyzed using Peto’s method as time-to-
event outcomes. For progression-free and overall survival, hazard ratios
derived from each trial using Cox regression were combined by inverse-
variance weighting. Five study questions (combined-modality treatment
vs. chemotherapy alone; more extended vs. involved-field radiotherapy;
radiation at higher doses vs. radiation at 20 Gy; more vs. fewer cycles of
the same chemotherapy protocol; standard-dose chemotherapy vs.
intensified chemotherapy) were investigated. After a median follow-up
of 7.4 years, dose-intensified chemotherapy resulted in better progres-
sion-free survival rates (P=0.007) as compared with standard-dose
chemotherapy, but was associated with an increased risk of therapy-
related acute myeloid leukemia/myelodysplastic syndromes (P=0.0028).
No progression-free or overall survival differences were observed
between combined-modality treatment and chemotherapy alone, but
more secondary malignant neoplasms were seen after combined-modal-
ity treatment (P=0.010). For the remaining three study questions, out-
comes and secondary malignancy rates did not differ significantly
between treatment strategies. The results of this meta-analysis help to
weigh up efficacy and secondary malignancy risk for the choice of first-
line treatment for Hodgkin lymphoma patients. However, final conclu-
sions regarding secondary solid tumors require longer follow-up.
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ABSTRACT
Introduction
Hodgkin lymphoma (HL) is a lymphoid malignancy
with an incidence of 3-4/100 000/year. Young adults are
most often affected.1 At present, about 80% of patients
achieve long-term remission after treatment with multi-
agent chemotherapy optionally followed by radiotherapy
(RT).2 Given the mostly young age at diagnosis and the
excellent long-term prognosis, therapy-related late effects
including secondary malignant neoplasms (SMN), cardio-
vascular disease and infertility have become increasingly
important.3-6 Several recent clinical trials evaluated the pos-
sibility of reducing toxicity by limiting chemotherapy and
RT without compromising efficacy.2 Conversely, some
studies for patients with newly diagnosed advanced HL
investigated intensified chemotherapy protocols to
improve the clinical outcome of high-risk patients.2
SMN are divided into secondary hematological malig-
nancies including therapy-related acute myeloid
leukemia/myelodysplastic syndromes (t-AML/MDS) and
secondary non-Hodgkin lymphomas (NHL) and the het-
erogeneous group of secondary solid tumors. An associa-
tion between the use of alkylating agents and topoiso-
merase II inhibitors and the development of t-AML/MDS
has been demonstrated.7-9 Both drug classes are included in
first-line chemotherapy protocols such as adriamycin,
bleomycin, vinblastine and dacarbazine (ABVD),
bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisone escalated (BEA-
COPP) and vinblastine, doxorubicin, vincristine,
bleomycin, mustard, etoposide, and prednisone (Stanford
V).10-12 For secondary NHL, such associations have not
been identified.13 The time interval between HL treatment
and the occurrence of secondary hematological malignan-
cies is usually short, ranging between four and ten years in
most cases.9,13 In contrast, the risk of secondary solid
tumors remains significantly increased for up to 25 years
and more.3,4
In the meta-analysis herein, using individual patient
data (IPD), SMN, progression-free survival (PFS) and over-
all survival (OS) of patients treated in randomized clinical
trials comparing different treatment approaches (com-
bined-modality treatment (CMT) vs. chemotherapy alone;
more extended radiotherapy (RT) vs. involved-field RT (IF-
RT); RT at higher doses vs. RT at 20 Gy; more vs. fewer
cycles of the same chemotherapy protocol; standard-dose
chemotherapy vs. intensified chemotherapy) were investi-
gated. Acceptable chemotherapy regimens were ABVD or
similar (e.g., mechlorethamine, vincristine, procarbazine
and prednisone/doxorubicin, bleomycin and vincristine
[MOPP/ABV]) or (for the last study question above) any
dose-intensified chemotherapy randomly compared with
a standard dose ABVD-like regimen. 
Methods
Searches for randomized clinical trials including patients with
newly diagnosed HL that compared treatment approaches accord-
ing to the mentioned study questions and published from 1984
onwards were performed in March 2010 using the electronic liter-
ature databases Medline and Cochrane Central. Reference lists of
all relevant retrieved publications and previous meta-analyses
were searched. All identified articles were screened independently
by two authors. Trials had to have enrolled at least 50 patients per
treatment group and to have finished recruitment before or during
2007, to avoid trials with inadequate follow-up. Searches were
repeated in April 2015.
IPD were requested from the investigators of the eligible trials,
including birth date, sex, HL diagnosis date, stage at diagnosis,
presence of B symptoms, randomization date, allocated treatment,
remission status after first-line treatment, relapse date, date and
type of SMN, death date and last follow-up date concerning clini-
cal outcome and vital status. 
Statistical methods
For quality control, each trial included in the meta-analysis was
initially analyzed separately, comparing the treatment arms with
respect to recruitment times, patient characteristics, complete
remission rates, follow-up duration, PFS, OS and time to SMN.
Results were compared with previous trial publications and incon-
sistencies were queried. Risk of bias was assessed for each trial
according to the Cochrane recommendations.14 To assess com-
pleteness of follow-up, the median observation time was calculat-
ed using the Kaplan-Meier method with reverse censoring at
death. The distribution of last information dates was quantified
using the interquartile range of the dates of last information (IQR-
DLI). This range includes the central 50% of last information dates
and thus represents the extent to which patients in a given study
are lost to follow up over a broad time interval. Large IQR-DLI val-
ues (absolute or relative to median follow-up) suggest poorer qual-
ity of follow up. 
Randomized comparisons for each study question were com-
bined across the appropriate trials to obtain a pooled Peto’s odds
ratio (OR) for SMN rates, with 95% confidence intervals (CI).15,16
Three types of SMN, i.e., t-AML/MDS, secondary NHL and sec-
ondary solid tumors were also analyzed separately. 
Subgroup analyses were performed to investigate whether the
SMN rates depended upon the stage according to Ann Arbor clas-
sification (early stages I and II vs. advanced stages III and IV), age
(≤50 years vs. >50 years) and sex. Treatment subgroups were
defined for the intensified chemotherapy question only (escalated
BEACOPP vs. Stanford V vs. epidoxirubicin, bleomycin, and vin-
blastine/lomustine, doxorubicin, and vindesine  (EBV/CAD)-based
vs. chlorambucil, vinblastine, prednisolone and procarbazine
(ChlVPP)-based). Results were displayed chronologically by
recruitment period in order to reveal time period effects.
Sensitivity analyses were conducted excluding SMN that had
occurred after HL recurrence: follow-up times were censored at
HL recurrence. Further sensitivity analyses were performed as fol-
lows: firstly, SMN data were analyzed using a one-step Cox pro-
portional hazards regression, stratified by trial, secondly, analyses
were repeated with the exclusion of the less complete follow-up
periods in each trial, censoring at the date at which 75% of surviv-
ing patients in the particular trial were still being followed, thirdly,
overall SMN and separate secondary solid tumor analyses were
repeated excluding non-melanoma skin cancers (NMSC), and
finally, the cumulative incidence method, which considers non-
SMN death as a competing risk, was employed.17,18
All analyses were performed in SAS (version 9.3) and RevMan
(version 5.2).
Results
Results of the search
A total of 3515 references (excluding duplicates) pub-
lished after 1984 were identified in 2010 and reviewed for
eligibility. The majority did not meet the predefined crite-
ria and were excluded for the following reasons: 1419 ref-
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erences did not concern HL patients, 1162 did not report a
clinical trial, 161 reported on patients in the second-line
setting, 98 reported non-randomized trials, 97 were
review articles, and 53 were duplicates. Hence, 578 refer-
ences fulfilled the predefined general eligibility criteria and
were reassessed concerning the exact treatment compari-
son. A total of 21 randomized clinical trials for the first-
line treatment of HL were identified, which included at
least 50 patients per study arm and compared treatment
modalities that matched with at least one of the five study
questions. Data were received for 16 trials conducted
between 1984 and 2007 (Figure 1).19-33 No data were
received for four studies.34-37 One additional trial first pub-
lished in 2013 was only found in the 2015 search, so IPD
were not sought.38 One trial was split for analysis since the
participating centers could choose between two alterna-
tive intensified chemotherapy regimens.32
Characteristics of the included studies
All included studies, grouped according to the study
questions, are described in Table 1.
Three aspects of the risk of bias (randomization, alloca-
tion concealment, attrition bias) according to the
Cochrane scheme were judged to be low in 13 out of 16
trials, while randomization and allocation concealment
were uncertain in two trials and considered high in one
trial. High risk of bias due to lack of blinding applied to all
trials with respect to SMN and PFS, OS was presumed to
D.A. Eichenauer et al.
1750 haematologica | 2017; 102(10)
Table 1. Description of included studies.
Comparison Study Stage Recruitment Follow Treatment arm N
(standard vs. up
experimental) Start Length Median Standard Experimental Total Standard Experi-
(y) (y) (y) mental
CMT vs. EORTC 20884 (19) IIIA-IVB 1989 10.7 9.0 6-8MOPP/ABV + IF 6-8MOPP/ABV 333 172 161
chemotherapy GHSG HD3 (24) IIIB-IVB 1984 4.2 12.9 3(COPP+ABVD) + IF 4(COPP+ABVD) 100 51 49
alone EORTC-GELA H9-F (21) IA-IIB 1998 5.75 6.6 6EBVP+ 20/36Gy IF 6EBVP 578 448 130
Extended vs. GHSG HD8 (25) IA-IIIA 1993 5 10.3 4COPP/ABVD + EF 4COPP/ABVD + IF 1064 532 532
involved-field RT Milan (30) IA-IIA 1990 6.5 17.5 4ABVD + STNI 4ABVD + IF 140 68 72
(after CT) EORTC-GELA H8-U (20) IA-IIB 1993 6 8.8 4MOPP/ABV + STNI 4/6MOPP/ABV + IF 984 324 660
HD94 Rome (31) IA-IIIA 1994 4 10.5 4ABVD + EF 4ABVD + IF 209 102 107
Higher dose GHSG HD10 (22) IA-IIB 1998 4.75 7.5 2/4ABVD + 30Gy IF 2/4ABVD + 20Gy IF 1163 575 588
vs. 20 Gy RT GHSG HD11 (23) IA-IIB 1998 4.75 7.4 4ABVD/4BEACOPP 4ABVD/4BEACOPP 1351 675 676
(after CT) +30Gy IF +20Gy IF
EORTC H9-F (21) IA-IIB 1998 5.75 6.6 6EBVP+36Gy IF 6EBVP+20Gy IF 448 239 209
More vs. fewer CT EORTC H8U (20) IA-IIB 1993 6 8.8 6MOPP/ABV + IF 4MOPP/ABV + IF 669 336 333
cycles EORTC H9-U (21) IA-IIB 1998 4 7.0 6ABVD +RT 4ABVD +RT 553 276 277
GHSG HD10 (22) IA-IIB 1998 4.75 7.5 4ABVD + 20/30Gy IF 2ABVD + 20/30Gy IF 1190 596 594
Standard-dose GHSG HD9 (26) IIB-IVB 1993 5.2 8.6 8COPP/ABVD 8BEACOPPesc 727 261 466
vs. intensified CT IIL HD9601 (28) IIB - IVB 1996 4.3 6.9 6ABVD Stanford V or 6MEC 335 122 213
(regimen +/- RT) GISL HD2000 (27) IIB-IVB 2000 7.25 3.5 6ABVD 6BEACOPP or 6CEC 295 99 196
GITIL-IIL NCT IB*, IIB-IVB 2000 7.0 4.6 6-8ABVD 4BEACOPPesc 331 168 163
01251107 (29) + 4BEACOPPbas
UKLG LY09 Hyb (32) IA-IVB 1998 3.7 7.9 6-8ABVD 6-8CHLVPP/EVA Hybrid 569 287 282
UKLG LY09 Alt (32) IA-IVB 1998 3.7 8.1 6/8ChlVPP/PABLOE 219 107 112
alternating
UKLG ISRCTN64141244 (33) I-IV** 1998 3.7 5.5 ABVD Stanford V 520 261 259
*only 1 patient, ** symptoms not specified. CMT: combined-modality treatment; RT: radiotherapy; CT: chemotherapy; y: year; IF: involved field; EF: extended field; STNI: subtotal
nodal irradiation; EORTC: European Organization for Research and Treatment of Cancer; GELA: Groupe d’Etude des Lymphomes de l’Adulte; GHSG: German Hodgkins' Study
Group; GISL: Gruppo Italiano per lo Studio dei Linfomi; GITIL: Gruppo Italiano di Terapie Innovative nei Linfomi; IIL: Intergruppo Italiano Linfomi; UKLG: United Kingdom National
Cancer Research Institute Lymphoma Group; MOPP/ABV: mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine; EBVP: epirubicin,
bleomycin, vinblastine, prednisone; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, prednisone; COPP/ABVD: cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine, dacarbazine; CEC: COPPEBVCAD: cyclophos-
phamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, bleomycin; MEC: MOPP/EBV/CAD: mechlorethamine, vincristine,
procarbazine, prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine, doxorubicin, vindesine; Stanford V: adriamycin, vinblastine, mechlorethamine, vincristine,
bleomycin, etoposide, prednisone; ChlVPP/PABlOE: chlorambucil, vinblastine, procarbazine, prednisolone/prednisolone, doxorubicin, bleomycin, vincristine, etoposide;
ChlVPP/EVA: chlorambucil, vinblastine, procarbazine, prednisolone/etoposide, vincristine, doxorubicin.
be entirely objective. Sixteen patients from two studies
with no evaluable data after randomization were excluded
from the meta-analysis.20,26 Those patients had also been
excluded from the analyses of the respective study groups.
The median follow-up within the trials ranged between
3.5 and 17.6 years (overall median follow-up: 7.4 years). A
histogram of follow-up times to SMN or last information
is displayed in the Online Supplementary Figure S1;
although 75% of patients had more than 5 years of fol-
low-up, only 16% were followed beyond ten years. A
comparison of the distribution of follow-up times
between the treatment arms of the included studies yield-
ed a significant difference according to the log-rank test
(P=0.036) in only one out of 16 cases. 
The IQR-DLI varied among trials from 0.4 to 6.6 years
(median: 3.1 years). Studies with longer follow-up tended
to have a wider scatter. The ratio between the IQR-DLI
and the median follow-up varied between 0.05 and 0.59
(median: 0.34). Thus, in half of the included studies the
central 50% of last information dates stretch over a time
interval of at least three years or one third of the median
follow-up duration.
Patient characteristics
IPD from 9498 patients treated within 16 randomized
clinical trials for newly diagnosed HL were included. At
the time of HL treatment, patients were aged between 14
and 75 according to inclusion criteria of the included stud-
ies (eight exceptions between ten and 87 years), median
age was 33 years. During the course of follow-up, an SMN
was reported for 438/9498 patients (4.6%), including 63 t-
AML/MDS (0.7%), 86 secondary NHL (0.9%) and 276
(2.9%) secondary solid tumors. The sites most often
affected were the breast (39/276), lung (35/276), skin
(29/276) and bowel (colon, rectum) (23/276). In 13 patients
(0.1%) diagnosed with an SMN, information on the tumor
entity was lacking. Cumulative incidences of SMN at five,
ten, 15 and 20 years (regarding death as a competing risk)
were 2.4%, 5.8%, 13% and 23%, respectively.
Results of the treatment comparisons
(1) CMT vs. chemotherapy alone
A total of 1011 patients treated within the European
Organisation for Research and Treatment of Cancer
(EORTC) 20884 (advanced stages), EORTC-Groupe
D'Etude des Lymphomes de L'Adulte (GELA) H9-F (early
stages) and the German Hodgkin Study Group  (GHSG)
HD3 (advanced stages) trials were analyzed. After a medi-
an follow-up of 7.8 years, 30/671 patients (4.5%) treated
with CMT and 10/340 patients (2.9%) treated with
chemotherapy alone had been diagnosed with an SMN.
This difference was significant, favoring patients who had
received chemotherapy only (P=0.010; Peto’s OR: 0.43,
95%-CI: 0.23-0.82) (Figures 2 and 3; Table 2). In particular,
patients aged 50 and younger (P=0.04), female patients
(P=0.01) and those with advanced stages (P=0.01) had a
significantly reduced risk of developing an SMN when
treated with chemotherapy alone. No reduced SMN rate
with chemotherapy alone was observed among patients
diagnosed with early stages (P=0.68). An analysis sepa-
rately evaluating the incidence rates for t-AML/MDS, sec-
ondary NHL and secondary solid tumors revealed a risk
reduction after chemotherapy alone solely for the devel-
opment of t-AML/MDS (P=0.037), but not for secondary
NHL and solid tumors (Table 3). The PFS and OS rates did
not significantly differ between treatment groups (Table
2), however, there was some evidence of inferior tumor
control with chemotherapy alone (HR: 1.31, 95%-CI:
0.99-1.73, P=0.06). Subgroup analyses indicated that stage
and age were significant effect modifiers (interaction 
P-values were <0.0001 (stage) and 0.02 (age)). PFS was sig-
nificantly impaired after chemotherapy alone in compari-
son with CMT for early-stage patients and patients aged
≤50 (Online Supplementary Tables S1, S2 and S3). 
(2) More extended RT vs. involved field RT
A total of 2397 early-stage patients treated within the
EORTC-GELA H8-U, the GHSG HD8, the Italian HD94
and the Milan trial were analyzed. After a median follow-
up of 10.8 years, 91/1026 patients (8.9%) who had
Secondary malignant neoplasms after HL treatment
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Figure 1. Search results (combined for both search-
es in 2010 and 2015). HL: Hodgkin lymphoma; IPD:
individual patient data.
received RT to more extended fields and 96/1371 patients
(7.0%) who had received IF-RT had been diagnosed with
an SMN. This difference was not statistically significant
(P=0.32; Peto’s OR: 0.86, 95%-CI: 0.64-1.16; Online
Supplementary Figures S2 and S3). In addition, when sepa-
rately analyzing the incidence rates of t-AML/MDS, sec-
ondary NHL and secondary solid tumors, there were no
significant differences between the treatment groups. The
same is true for the PFS and OS rates (Table 2). Subgroup
analyses according to sex and age did not identify any het-
erogeneity of the treatment effect across any subgroups.
(3) RT at higher doses vs. RT at 20 Gy
A total of 2962 early-stage patients treated within the
EORTC-GELA H9-F, GHSG HD10 and GHSG HD11 trials
were analyzed. After a median follow-up of 7.4 years,
54/1489 patients (3.6%) who had RT at a dose of 30 Gy or
36 Gy and 56/1473 patients (3.8%) who had RT at a dose
of 20 Gy had developed an SMN. Thus, the rate of SMN
D.A. Eichenauer et al.
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Figure 2. Additional radiotherapy, cumulative incidence of SMN (Peto meta-analysis). CI: confidence interval; O-E: observed minus expected; V: variance; I2 = meas-
ure of heterogeneity: EORTC: European Organization for Research and Treatment of Cancer; GHSG: German Hodgkins' Study Group.
Table 2. Treatment effect and heterogeneity for secondary malignant neoplasms (SMN), overall survival (OS) and progression-free survival (PFS).
Summary of main results
Comparison SMN OS PFS
(standard vs. OR I2 N HR I2 N HR I2 N
experimental) (95%-CI) (95%-CI) (95%-CI)
CMT vs. 0.433 30 0.71 53 
chemotherapy alone (0.28-0.82) 0% (4.5%) (0.46- 1.11) 39% (7.9%) 1.31 123
vs. 10 vs. 31 (0.99-1.73) 89% (18.3%) 
(2.9%) (9.1%) vs. 83
(24.4%)
Extended vs. 0.862 92 0.89 132 0.99 175
involved-field RT (0.64-1.16) 67% (9.0%) (0.70-1.12) 0% (12.9%) (0.81-1.21) 0% (17.1%) 
(after CT) vs. 96 vs. vs. 224 
(7.0%) 155 (11.3%) (16.3%)
Higher dose vs. 20 Gy RT 1.032 54 0.91 72 1.20 165
(after CT) (0.71-1.50) 72% (3.6%) (0.65-1.28) 0% (4.8%) (0.97-1.48) 1% (11.1%)
vs. 56 vs. vs. 190 
(3.8%) 66 (4.5%) (12.9%)
More vs. fewer 1.096 48 0.99 82 (6.8%) 1.15 133
CT cycles (0.74-1.62) 0% (4.0%) (0.73-1.34) 0% vs.  (0.91-1.45) 31% (11.0%)
vs. 53 82 vs. 152
(4.4%) (6.8%) (12.6%)
Standard-dose 1.37 31 0.85 191 0.82 350
vs. intensified CT (0.89%- 11% (2.4%) vs. 60 (0.70 – 63% (14.6%) (0.70 – 85% (26.8%)
(regimen +/- RT) 2.10) (3.6%) 1.04) vs. 213 0.95) vs. 372
(12.6%) (22.0%)
CMT: combined-modality treatment; RT: radiotherapy; CT: chemotherapy; OR: odds ratio by Peto method, HR: hazard ratio by Cox regression; CI: confidence interval; I2: heterogene-
ity; N: number of events.
Favors chemo. alone
(P=0.88)
(P=0.88)
(P=0.01)
(P=0.01)
(P=0.63)
(P=0.68)
Favors chemo-radio
did not differ between the treatment groups (P=0.87;
Peto’s OR: 1.03, 95%-CI: 0.71-1.50; Online Supplementary
Figures S4 and S5). There were also no differences when
the rates for t-AML/MDS, secondary NHL and secondary
solid tumors were separately considered. The clinical out-
come was similar in both treatment groups, with no dif-
ferences in PFS and OS. Additional subgroup analyses
according to sex and age did not identify differences
between any subgroups.
(4) More vs. fewer cycles of the same chemotherapy protocol 
A total of 2403 early-stage patients treated within the
EORTC-GELA H8-U, EORTC-GELA H9-U and GHSG
HD10 trials were analyzed. After a median follow-up of
7.8 years, 48/1201 patients (4.0%) who had been treated
with more cycles and 53/1202 patients (4.4%) who had
received fewer cycles of the same chemotherapy protocol
had developed an SMN. This difference was not statisti-
cally significant (P=0.65; Peto’s OR: 1.10, 95%-CI: 0.74-
1.62) (Online Supplementary Figures S6 and S7).
Additionally, the SMN incidences did not differ between
the patient groups when t-AML/MDS, secondary NHL
and secondary solid tumors were  considered separately.
The clinical outcome after treatment with more or fewer
cycles of the same chemotherapy was comparable, with-
out any significant PFS and OS differences. Additional
subgroup analyses according to sex and age did not iden-
tify differences between any subgroups.
(5) Standard-dose chemotherapy (ABVD or  cyclophosphamide
vincristine, procarbazine, and prednisone (COPP)/ABVD) vs.
intensified chemotherapy
A total of 2996 advanced-stage patients treated within a
Gruppo Italiano Terapie Innovative nei Linfomi 
(GITIL)-Intergruppo Italiano Linfomi (IIL) trial, the
Gruppo Italiano per lo Studio dei Linfomi  (GISL) HD2000
trial, the GHSG HD9 trial, the HD9601 trial from Italy and
the British LY09 and ISRCTN64141244 trials were ana-
lyzed. The rates of RT were comparable in both treatment
groups of the included studies with the exception of the
ISRCTN64141244 and HD9601 trials, administering
Stanford V as an  intensified regimen. After a median fol-
low-up of 6.7 years, 31/1305 patients (2.8%) who had
received standard-dose chemotherapy (ABVD,
COPP/ABVD) and 60/1691 patients (3.5%) treated with
intensified chemotherapy protocols (escalated BEACOPP,
Stanford V, ChlVPP/prednisolone, doxorubicin,
bleomycin, vincristine, and etoposide  (PABIOE),
ChlVPP/etoposide, vincristine, and doxorubicin  (EVA),
MOPP/EBV/CAD, COPP/EBV/CAD) had developed an
SMN. This difference was not statistically significant
(P=0.15; Peto’s OR: 1.37, 95%-CI: 0.89-2.10; Figures 4 and
5). When considering t-AML/MDS, secondary NHL and
secondary solid tumors separately, an increased risk to
develop t-AML/MDS was seen for patients treated with
intensified chemotherapy protocols (P=0.0028), whereas
the incidence rates for secondary NHL and secondary
solid tumors did not differ between the treatment groups
(Table 3). Overall, tumor control was significantly better
with intensified chemotherapy regimens as compared
with standard-dose protocols (P=0.007; HR: 0.82, 95%-CI:
(0.70 – 0.95)) while there were no significant differences in
OS (P=0.12; HR: 0.85, 95%-CI: (0.70 – 1.04)). However,
subgroup analyses revealed that patients aged ≤50, in par-
ticular, appear to benefit from more aggressive chemother-
apy approaches as the improved PFS also translated into a
Secondary malignant neoplasms after HL treatment
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Figure 3. Additional radiotherapy, cumulative incidence of SMN (Peto meta-analysis). Vertical bars depict approximate 95% confidence intervals (CI) for cumulative
incidence rates. CT: chemotherapy; RT: radiotherapy.
better OS in these patients (P=0.02). In contrast with
patients older than 50 years, patients aged ≤50 also had a
significantly greater SMN risk with intensified chemother-
apy protocols than with standard-dose chemotherapy
(interaction P=0.02; treatment effect in younger subgroup:
P=0.01). Additional subgroup analyses revealed differ-
ences between the different intensified protocols for PFS
(interaction P<0.00001) and OS (interaction P=0.006).
Patients treated with escalated BEACOPP had superior
PFS and OS rates in comparison with those receiving stan-
dard-dose chemotherapy. For Stanford V, PFS was worse
than with standard-dose chemotherapy. No PFS and OS
differences in comparison with standard-dose chemother-
apy were observed for ChlVPP/PABIOE, ChlVPP/EVA,
MOPP/EBV/CAD and COPP/EBV/CAD. For SMN no
interaction in chemotherapy subgroups were found (inter-
action P=0.06; Online Supplementary Table S3).
All of the main meta-analytic results are summarized in
Table 2.
Sensitivity analyses agreed with the described main
analyses. The results of sensitivity analyses concerning
censoring of incomplete follow-up periods and exclusion
of NMSC are summarized in Online Supplementary Tables
S4 and S5. 
Discussion
The meta-analysis herein, including 9498 patients treat-
ed within 16 randomized clinical trials for newly diag-
nosed HL between 1984 and 2007, represents one of the
largest analyses of SMN, PFS and OS of HL patients based
on randomized comparisons. The major findings were as
follows: (1) after a median follow-up of 7.4 years, the
overall SMN rate was 4.6%, (2) compared with patients
receiving chemotherapy alone, an increased SMN rate
was observed in patients receiving CMT, (3) patients with
early-stage HL treated with CMT had a better PFS than
patients treated with chemotherapy alone, (4) compared
with patients receiving standard-dose chemotherapy,
those receiving intensified chemotherapy protocols devel-
oped t-AML/MDS more often, and (5) compared with
ABVD-like protocols, PFS and OS in advanced-stage
patients were improved with escalated BEACOPP, but
higher rates of SMN were observed.
The overall SMN rate of 4.6% in the meta-analysis here-
in was lower than in previous reports. A meta-analysis
from our group included a total of 9312 patients treated
between 1962 and 2000. After median follow-up times
ranging between four and 32 years for the considered tri-
als, the overall SMN rate was 7.6%.39,40 A British analysis
including 5798 patients treated between 1963 and 2001
reported an SMN rate of 7.9%.4 According to a Dutch
study with a median follow-up of 19.1 years, the overall
SMN rate was 23% and the risk for the development of an
SMN was still increased 30 years after HL treatment.3 Two
reasons likely contribute to the higher SMN rates in these
previous analyses: (1) a relevant proportion of the expect-
ed secondary solid tumors that are often diagnosed ten or
more years after HL treatment has not yet occurred in the
patients included in the meta-analysis herein due to the
limited median follow-up of 7.4 years, and (2) the SMN
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Figure 4. Intensified chemotherapy, secondary malignant neoplasms, forest plot for Peto Odds Ratios. CI: confidence interval; O-E: observed minus expected; V:
variance, I2: measure of heterogeneity; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine.
Table 3. Summary of SMN results for each SMN type.
Comparison
(standard vs. Solid tumor t-AML/MDS NHL
experimental)
OR P OR P OR P
CMT vs. chemotherapy alone 0.627 0.29 0.293 0.037 0.325 0.21
Extended vs. involved-field RT (after CT) 0.851 0.37 0.517 0.14 1.18 0.66
Higher dose vs. 20 Gy RT (after CT) 1.20 0.43 0.662 0.65 0.845 0.67
More vs. fewer CT cycles 1.15 0.56 0.261 0.10 1.94 0.13
Standard-dose vs. intensified CT (regimen +/- RT) 1.00 1.0 4.51 0.0028 0.61 0.26
t-AML/MDS: therapy-related acute myeloid leukemia/myelodysplastic syndromes; NHL: non- Hodgkin lymphomas; CMT: combined-modality treatment; RT: radiotherapy; CT:
chemotherapy; OR: Peto odds ratio; P: P-value. 
Favors dose-intensified Favors ABVD-like
(P=0.35)
(P=0.15)
rate observed within the present meta-analysis is probably
truly lower than the rates seen in the older analyses, since
in recent years RT fields and doses were reduced and
chemotherapy protocols were modified with the aim of
decreasing the SMN risk. 
In the meta-analysis herein, patients receiving CMT for
HL had a significantly increased risk to develop an SMN
when compared with chemotherapy alone. Figure 3
shows that at ten years after first-line treatment, the
absolute cumulative SMN risks are approximately 3% and
10%, a risk difference of 7%. This result is in line with
previous analyses such as the above mentioned British
study, in which patients treated with chemotherapy alone
had a significantly lower relative risk for the development
of an SMN than patients receiving CMT.4 Subgroup analy-
ses of the analysis herein considering t-AML/MDS, sec-
ondary NHL and secondary solid tumors separately,
detected a significantly increased risk after CMT for t-
AML/MDS only, but not for secondary NHL and second-
ary solid tumors. This finding is consistent with older
reports, including a study from Italy comprising 1659
patients treated with RT alone, CMT or chemotherapy
alone. At 15 years, the t-AML/MDS rate after CMT was
significantly higher than after chemotherapy alone
(P=0.05).41
According to the meta-analysis herein, patients diag-
nosed with early-stage HL had a better PFS after CMT
than after chemotherapy alone. However, this finding has
to be interpreted with caution as it derives from only one
of the included trials. Nonetheless, similar data also came
from the randomized EORTC/Lymphoma Study
Association (LYSA)/Fondazione Italiana Linfomi (FIL) H10
study and the RAPID trial conducted in the UK. These
studies evaluated the  positron emission tomography
(PET)-guided omission of consolidating RT after
chemotherapy in patients with early-stage HL. Both stud-
ies additionally revealed a significantly increased event
rate after chemotherapy alone in patients with a good
response to chemotherapy resulting in a negative interim
PET.42-44 Additional data supporting the use of CMT in
early-stage HL come from a previous Cochrane systematic
review including 1245 patients from five randomized
studies and an analysis comprising 20600 patients regis-
tered in the U.S. National Cancer Data Base, both of
which have not only demonstrated a better PFS but also
an improved OS among patients treated with CMT com-
pared with chemotherapy alone.45,46
In the meta-analysis herein, an increased t-AML/MDS
rate was seen in patients receiving intensified chemother-
apy compared with patients treated with standard-dose
chemotherapy. This finding is consistent with other
reports on t-AML/MDS after HL treatment. An analysis
by the GHSG, including 11952 patients treated within
prospective studies for newly diagnosed HL, demonstrat-
ed that patients receiving no BEACOPP or up to four
cycles of escalated BEACOPP had significantly lower
cumulative t-AML/MDS rates than patients treated with
four or more cycles of escalated BEACOPP (0.3% vs. 0.7%
vs. 1.7%; P<0.0001).7
For escalated BEACOPP, the increased t-AML/MDS risk
contrasts with an improved clinical outcome. PFS
(P<0.00001) and OS (P=0.0005) rates were better than
those seen with standard-dose protocols, i.e., ABVD or
COPP/ABVD. This is in line with the results of a network
meta-analysis on the effect of the initial treatment strategy
on the survival of patients with advanced HL. That analy-
sis, which included a total of 9993 patients, revealed a sur-
vival advantage of 10% at five years for escalated BEA-
COPP in comparison with ABVD.47
Generally, this meta-analysis provides high-quality evi-
dence on SMN, PFS and OS among patients treated for
HL, as the used data are from participants of large ran-
domized trials for the first-line treatment of HL. However,
the analysis has some limitations. With a median overall
follow-up of 7.4 years, valid estimates are only possible
for secondary hematological malignancies, whilst final
conclusions regarding secondary solid tumors that often
occur more than ten years after HL cannot be drawn. The
Secondary malignant neoplasms after HL treatment
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Figure 5. Intensified chemothera-
py, cumulative incidence of SMN
(Peto meta-analysis). Vertical bars
depict approximate 95% confi-
dence intervals (CI) for cumulative
incidence rates. ABVD: doxorubicin,
bleomycin, vinblastine, dacar-
bazine.
long-term data of HL patients treated within clinical trials
are therefore necessary but often difficult to obtain due to
different factors, including a limited duration of insurance
for study participants and a lack of funding sources. There
is also some uncertainty about the completeness of SMN
reporting which is of particular importance due to the
small number of SMN events. Finally, for certain out-
comes and study questions there was a considerable het-
erogeneity of up to 89% between the included trials,
which signifies that the overall meta-analytic results may
not apply in all situations.
Nonetheless, given the relevant proportion of HL
patients that have already developed an SMN  after a
median observation of 7.4 years, the present report
underscores the need for treatment approaches allowing
a more accurate allocation to defined risk groups, in order
to prevent overtreatment and reduce the risk of the devel-
opment of potentially fatal SMN. At present, interim PET
is considered the most promising tool to stratify treat-
ment. Some mature results addressing this issue are
already available and additional studies will be analyzed
in the near future.48,49 The replacement of conventional
chemotherapy by novel agents such as the CD30-directed
antibody-drug conjugate brentuximab vedotin and anti-
bodies targeting the programmed death cell protein 1
(PD-1) may also reduce the risk for the development of
SMN.50,51 
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